In early December, VMT-α-NET, the Company’s lead drug for the treatment of neuroendocrine tumors was administered to patients in India on a compassionate use basis, independent of a planned US trial…
In early December, VMT-α-NET, the Company’s lead drug for the treatment of neuroendocrine tumors was administered to patients in India on a compassionate use basis, independent of a planned US trial…
CEO Lori Woods with Proactive financial media discussing the Isoray merger with Viewpoint Molecular Targeting, Inc. and the big opportunity it represents in 2023
Always strive for better work. Never stop learning. Have fun a clear plan for a new project or just an idea on a napkin? Sky, land, and sea disappear together out of the world…
Always strive for better work. Never stop learning. Have fun a clear plan for a new project or just an idea on a napkin? Sky, land, and sea disappear together out of the world…
